Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Prostatic Neoplasms 3Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Endometrial Adenocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

Sunitinib 145Nivolumab 144pembrolizumab 132Sorafenib 84Bevacizumab 77Everolimus 74cabozantinib 71pazopanib 65Axitinib 65Ipilimumab 62aldesleukin 52Magnetic Resonance Spectroscopy 45Cyclophosphamide 40Interleukin-2 38lenvatinib 37Specimen Handling 36Radiosurgery 36Interferon-alpha 32atezolizumab 30temsirolimus 27belzutifan 24Gemcitabine 23fludarabine phosphate 22avelumab 22Radiotherapy 19Interferon alpha-2 19Biopsy 18fludarabine 17durvalumab 17Nephrectomy 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × nintedanib × Genitourinary × Clear all
NCT01024920 2021-07-19

Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Boehringer Ingelheim

Phase 2 Completed
99 enrolled 45 charts
Genitourinary

Carcinoma, Renal Cell

NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1 Completed
21 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡